Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mind Medicine Mindmed Inc (NQ: MNMD ) 6.360 -0.060 (-0.93%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mind Medicine Mindmed Inc < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Preview: Mind Medicine's Earnings November 01, 2023 Via Benzinga Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More October 29, 2023 Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted Via Benzinga Topics Intellectual Property Exposures Intellectual Property MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update October 26, 2023 From Mind Medicine (MindMed) Inc. Via Business Wire MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) October 24, 2023 From Mind Medicine Inc. Via Business Wire Analyst Expectations for Mind Medicine's Future October 23, 2023 Via Benzinga Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted October 22, 2023 Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts Via Benzinga Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More October 16, 2023 Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Via Benzinga Exposures Product Safety Psychedelic-Compound-Based Drug Stocks Continue To Fall October 15, 2023 The 5 constituents in our Psychedelic Drug Stocks Index were down 10.1% this week (-6.3% last week) and are now down 39.2% since the end of July. Via Talk Markets 3 Pharma Stocks to Dump Before the Damage Is Done October 08, 2023 There's never a shortage of pharma stocks to sell due to the nature of the sector, especially when compounded by current fears. Via InvestorPlace Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More October 06, 2023 Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares Via Benzinga Major Psychedelic Drug Stocks Continued To Decline This Week October 06, 2023 A review of the performances of the 5 stocks in the Psychedelic Drug Stocks Index this week and since the end of August along with links to their latest news. Via Talk Markets MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress October 03, 2023 From Mind Medicine Inc Via Business Wire Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... Via Benzinga September Summary: Largest Psychedelic Drug Stocks Dropped 14% October 01, 2023 Seelos Therapeutics' market capitalization dropped below $50M with the recent dramatic decline in its share price and, as such, is no longer part of the Psychedelic Drug Stocks Index. The remaining... Via Talk Markets Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More September 26, 2023 Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Via Benzinga Topics Economy Exposures Interest Rates Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price September 24, 2023 With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and... Via Talk Markets The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis September 19, 2023 EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END Via FinancialNewsMedia Topics Economy Exposures Economy Product Safety Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise September 20, 2023 EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Intellectual Property Exposures Death Intellectual Property Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More September 18, 2023 Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next Via Benzinga Exposures Product Safety Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update September 18, 2023 Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). Via Benzinga 4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week September 17, 2023 4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week... Via Talk Markets MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit September 14, 2023 From MindMed Via Business Wire Combining MDMA With Psilocybin Or LSD Could Reduce Difficult Trips, New Study Shows September 13, 2023 Recent peer-reviewed research published in the journal Nature posits that a small dose of MDMA could be helpful against uncomfortable or difficult experiences and amplify positive ones when combined... Via Benzinga NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years September 12, 2023 NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. Via Benzinga MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone September 12, 2023 MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders, Via Benzinga MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) September 12, 2023 From Mind Medicine (MindMed) Inc. Via Business Wire Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence 6 Largest Psychedelic Compound-Based R & D Stocks In Decline September 10, 2023 The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. Via Talk Markets The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction September 07, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property 6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week September 05, 2023 The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. Via Talk Markets < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.